Taltz is supplied as 80mg of ixekizumab per mL in a single-dose prefilled autoinjector or syringe. ... Taltz. Package insert. Eli Lilly and Company; 2022. Accessed August 8, 2022.

Taltz sales jumped 37%, to $420 million, also beating estimates. For the year, the company reported profit of $8.32 billion, or $8.89 per share. Revenue was reported as $22.32 billion.

Ixekizumab has taken a major step toward its approval for the treatment of psoriatic arthritis and enthesitis-related arthritis in children, based on positive data from a phase 3 trial.

As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth By Eric Sagonowsky Oct 26, 2021 11:44am Alzheimer's Diabetes Eli Lilly Emgality ...

--Eli Lilly and Company today announced its financial results for the third quarter of 2024.. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding ...